CWS Financial Advisors LLC Purchases 797 Shares of Zoetis Inc. $ZTS

19 Aug 2025, 10:14 by Renee Jackson · The Cerbat Gem

CWS Financial Advisors LLC raised its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 27.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,746 shares of the company’s stock after buying an additional 797 shares during the quarter. CWS Financial Advisors LLC’s holdings in Zoetis were worth $617,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Portside Wealth Group LLC raised its position in shares of Zoetis by 24.7% in the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock valued at $5,550,000 after purchasing an additional 6,672 shares during the period. Tandem Investment Advisors Inc. raised its stake in shares of Zoetis by 100.3% during the 1st quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock valued at $65,140,000 after purchasing an additional 198,089 shares during the period. Flagship Harbor Advisors LLC raised its stake in shares of Zoetis by 31.2% during the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock valued at $1,217,000 after purchasing an additional 1,760 shares during the period. Horizon Financial Services LLC bought a new stake in shares of Zoetis during the 1st quarter valued at $380,000. Finally, Sage Rhino Capital LLC raised its stake in shares of Zoetis by 117.6% during the 1st quarter. Sage Rhino Capital LLC now owns 7,014 shares of the company’s stock valued at $1,155,000 after purchasing an additional 3,791 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Down 1.2%

ZTS opened at $152.28 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. The stock has a market cap of $67.49 billion, a PE ratio of 26.21, a P/E/G ratio of 2.47 and a beta of 0.88. The business’s fifty day simple moving average is $154.69 and its 200 day simple moving average is $158.90. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period last year, the business earned $1.56 earnings per share. The business’s quarterly revenue was up 4.2% on a year-over-year basis. As a group, research analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be paid a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Insider Activity

In related news, EVP Roxanne Lagano sold 652 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares in the company, valued at $2,571,930. This trade represents a 4.13% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ZTS. Piper Sandler upped their price target on Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 17th. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price target for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Leerink Partners lowered Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, UBS Group decreased their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 7th. Four research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, Zoetis presently has an average rating of “Moderate Buy” and an average price target of $202.43.

Get Our Latest Stock Report on Zoetis

Zoetis Profile

(Free Report)

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.